Curocell Inc. (KOSDAQ:372320)

South Korea flag South Korea · Delayed Price · Currency is KRW
28,600
+350 (1.24%)
At close: Jun 11, 2026
Market Cap438.51B +5.6%
Revenue (ttm)n/a
Net Income-48.20B
EPS-3,337.30
Shares Out 15.23M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume33,185
Open27,350
Previous Close28,250
Day's Range27,150 - 28,650
52-Week Range26,550 - 66,000
Beta0.60
Analystsn/a
Price Targetn/a
Earnings DateAug 13, 2026

About Curocell

Curocell Inc., a cell gene therapy development company, engages in the development and manufacturing of pharmaceuticals. It provides research and development services; and OVercome Immune Suppression (OVIS), a proprietary platform technology designed to get away from exhaustion induced by immune checkpoint receptors. The company is also involved in the development of CD19 CAR-T treatment, blood cancer CAR-T, solid cancer CAR-T, and allogeneic CAR-T. Curocell Inc. was founded in 2016 and is headquartered in Daejeon, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 372320
Full Company Profile

Financial Performance

Financial Statements